贝伐珠单抗联合FOLFOX6一线治疗转移性结直肠癌的疗效及安全性分析

Efficacy and safety of bevacizumab combined with FOLFOX in the treatment of metastatic colorectal cancer

目的分析贝伐珠单抗联合化疗治疗转移性结直肠癌的疗效和安全性。方法将68例转移性结直肠癌患者通过随机抽样法分为观察组和对照组各34例。对照组仅给予FOLFOX6方案化疗进行治疗,观察组在此基础上给予贝伐珠单抗进行治疗,对比2组患者的临床疗效以及安全性。结果观察组客观有效率、疾病控制率均高于对照组,差异均有统计学意义(P<0.05)。2组不良反应发生率对比差异无统计学意义(χ~2=0.806,P>0.05)。结论贝伐珠单抗联合FOLFOX治疗转移性结直肠癌具有较好的临床疗效,且不良反应发生率较低,安全性高,值得在临床广泛应用。

Objective To evaluate the efficacy and safety of bevacizumab combined with chemotherapy in the treatment of metastatic colorectal cancer. Methods 68 patients with metastatic colorectal cancer were randomly divided into observation group and control group,each of 34 cases. Control group was treated only with chemotherapy,on the basis of which the observation group was treated with bevacizumab. The clinical efficacy and safety of two groups were compared. Results The objective efficiency and disease control rates in observation group were higher than those in control group,the difference was statistically significant（ P〈0. 05）. There was no significant difference in the incidence of adverse reactions between two groups（ χ^2= 0. 806,P〉0. 05）. Conclusion The treatment of bevacizumab combined with FOLFOX in metastatic colorectal cancer has a good of the clinical efficacy,and the incidence of adverse reactions is low,high security,worthy of clinical widely used.